ENTA News and Press, Enanta Pharmaceuticals Inc. From 09/07/23

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial v...

Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK , Se...

2023-09-01 18:33:42 ET More on Airbnb and Blackstone Airbnb: Upgrading To Hold, Headwinds Priced In How To Think About Airbnb Blackstone: Load Up Before It Recovers Its All-Time Highs (Rating Upgrade) Blackstone: Time For A Rating Downgrade Airbnb: Ev...

2023-08-09 15:34:02 ET JP Morgan has downgraded Enanta Pharmaceuticals ( NASDAQ: ENTA ) to neutral, citing extended commercialization timelines for its COVID-19 and RSV treatment candidates. The investment bank said it sees a challenging road ahead for the company's COVID-19 dru...

2023-08-08 16:54:17 ET Jefferies has downgraded Enanta ( NASDAQ: ENTA ) to hold, citing concerns that the company won't be able to find a commercial partner for its COVID-19 treatment EDP-235. The investment bank said it was wary of Enanta's plan not to move EDP-235 into Phase 3...

2023-08-08 14:23:06 ET Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is down more than 62% so far this year. Enanta focuses on f...

2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...

2023-08-07 20:42:10 ET Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Results Conference Call August 07, 2023 04:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer...

2023-08-07 16:02:32 ET Enanta Pharma press release ( NASDAQ: ENTA ): Q3 GAAP EPS of -$1.86 beats by $0.47 . Revenue of $18.89M (-3.0% Y/Y) beats by $2.15M . For further details see: Enanta Pharma GAAP EPS of -$1.86 beats by $0.47, revenue of $18.89M beats...

Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. Cash and Marketable Securities Totaled $392.5 ...